Axtria Blog

Axtria features in Gartner’s SPM Magic Quadrant for the Second Year in a row!

Gartner has just released the latest version of the Magic Quadrant for Sales Performance Management. The Magic Quadrant examines qualifying vendors for sales performance management including: incentive compensation, quota management, and territory management. This annual report evaluates vendors based on both vision and execution strength.

Read More

Is NBRx Data the Right Choice for Your IC Plan?

We all know that in sales, the outcomes you get are the outcomes you incent. This is especially important for large field forces such as pharma, where a very large number of influencers are being targeted and compensation is computed based on terabytes of external data! Good incentive compensation plans combined with well administered execution can motivate the sales force and drive the right behaviors to align with corporate goals. But how do we know if the measures we’ve selected contribute to an intelligent plan design?

Read More

Sales Operations Excellence With Intelligent Roster Management

Effective roster management has long been an overlooked topic in Pharma commercial operations. In fact, in our 2016 Commercial Excellence Survey, we found that 46% of Pharma organizations still don’t have integrated processes to manage their sales rep to territory mappings. At any point in time, it is critical for the Sales Operations business processes to have access to the latest and distinct set of sales personnel that will need to be accounted for.

Read More

PMSA January Symposium 2018 - Multi-Channel Marketing and Next Generation Engagement

We are excited to share that Axtria will be running a workshop on Multi-Channel Marketing and Next Generation Engagement at the upcoming PMSA January Symposium in Las Vegas.

Read More

Axtria makes the NJBIZ Fast 50 list for the fourth consecutive year

We are proud to share that Axtria has made NJBIZ’s Fast 50 list of the fastest growing companies in New Jersey. It is our fourth year on the list, and we are ranked 11th for 2017.

Read More

Axtria Ranks in Deloitte’s Technology Fast 500™, yet Again!

At Axtria we are very excited to have been ranked number 270 on Deloitte’s Technology Fast 500™ list for 2017. This recognition marks Axtria’s third consecutive year amongst Deloitte’s fastest growing companies, and we are honored and extremely proud of this achievement. 

Read More

Axtria ranks in CIOReview’s 20 Most Promising Pharma and Life Sciences Tech Solution Providers 2017 list

Axtria is extremely proud to rank in the CIOReview Tech Solution Providers list for 2017, which is an annual listing of 20 companies that are at the forefront of providing Pharma and Life Science solutions and impacting the market.

Read More

Axtria Ranks in Crain’s Fast 50 New York Companies

Axtria is extremely proud to rank in Crain’s New York Business Fast 50 List for 2017. The ranking highlights the city's 50 fastest-growing companies with its annual Fast 50 feature. It celebrates the success of innovative companies and recognizes their business strategies and accelerated revenue growth.

Read More

Insightful HEOR analysis for the cardiovascular community

Some of the most rewarding work we are involved in at Axtria right now is in the Health Economics and Outcomes Research (HEOR) space, where we are partnering with our clients to help demonstrate the value of their medications and get them to the patients who need them. Challenges in the healthcare space—including rising costs, an aging population, advanced technology, and increased patient awareness of medical options—have resulted in an increase in evaluating medications from an HEOR perspective. Through our modelling and analytical work, we work with clients and key opinion leaders (KOLs) to identify which patients would benefit from various treatment options and the impact those treatments could have on patient health.

Read More

Newsletter Sign-Up

FOLLOW

Recent Posts